{"id":1584,"date":"2018-06-24T22:09:12","date_gmt":"2018-06-24T21:09:12","guid":{"rendered":"http:\/\/ibb.uab.cat\/?p=1584"},"modified":"2018-06-24T22:09:12","modified_gmt":"2018-06-24T21:09:12","slug":"self-assembling-toxin-based-nanoparticles-as-self-delivered-antitumoral-drugs","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2018\/06\/24\/self-assembling-toxin-based-nanoparticles-as-self-delivered-antitumoral-drugs\/","title":{"rendered":"Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs"},"content":{"rendered":"
<\/p>\n
Loading capacity and drug leakage from vehicles during circulation in blood is a major concern when developing nanoparticle-based cell-targeted cytotoxics<\/a>. To circumvent this potential issue it would be convenient the engineering of drugs as self-delivered nanoscale entities, devoid of any heterologous carriers. In this context, we have here engineered potent protein toxins<\/a>, namely segments of the diphtheria toxin<\/a> and the Pseudomonas aeruginosa<\/em> exotoxin<\/a> as self-assembling, self-delivered therapeutic materials targeted to CXCR4+<\/sup> cancer stem cells<\/a>. The systemic administration<\/a> of both nanostructured drugs in a colorectal cancer xenograft mouse model promotes efficient and specific local destruction of target tumor tissues and a significant reduction of the tumor volume. This observation strongly supports the concept of intrinsically functional protein nanoparticles<\/a>, which having a dual role as drug and carrier, are designed to be administered without the assistance of heterologous vehicles.<\/p>\n<\/div>\n<\/div>\n